Exelixis, Inc.(EXEL) Stock Research - Grey Stern Research

Exelixis, Inc. (EXEL) Stock Analysis

$37.27 (4.54%)

EXEL Financial Performance


Use the table below to view Exelixis, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $37.27 -
52 Week Low $20.02 -
52 Week High $37.31 -
Market Cap $10.6 Billion 5/18
Gross Margin 96% 5/18
Profit Margin 25% 5/18
EBITDA margin 28% 2/18
Q3 - 2024 Revenue $478.1 Million 3/18
Q3 - 2024 Earnings $118.0 Million 4/18
Q3 - 2024 Free Cash Flow $296.1 Million 2/18
Trailing 4 Quarters Revenue $2.0 Billion 3/18
Trailing 4 Quarters Earnings $466.9 Million 2/18
Quarterly Earnings Growth 11233% 2/18
Annual Earnings Growth 91% 4/18
Quarterly Revenue Growth 1% 8/18
Annual Revenue Growth 7% 10/18
Cash On Hand $258.3 Million 8/18
Short Term Debt $3.3 Million 18/18
Long Term Debt $194.4 Million 7/18

Exelixis, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Exelixis, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 22.79 3/18
PS 5.27 12/18
PB 4.68 10/18
PC 41.20 6/18
Liabilities to Equity 0.30 12/18
ROA 0.16 2/18
ROE 0.21 4/18
Current Ratio 4.32 5/18
Quick Ratio 1.74 5/18
Long Term Debt to Equity 0.09 10/18
Debt to Equity 0.09 9/18
Burn Rate -2.33 15/18
Cash to Cap 0.02 13/18
CCR 2.51 2/18
EV to EBITDA 77.75 4/18
EV to Revenue 5.24 12/18

Company Details

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

CEO: Dr. Michael Morrissey

Website: https://www.exelixis.com

Address: 1851 Harbor Bay Pkwy Alameda, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Exelixis, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Exelixis, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $32.4 Billion
BioMarin Pharmaceutical Inc. BMRN $11.7 Billion
Halozyme Therapeutics, Inc. HALO $6.9 Billion
Viking Therapeutics, Inc. VKTX $3.9 Billion
Reata Pharmaceuticals, Inc. RETA $6.6 Billion
TG Therapeutics, Inc. TGTX $4.7 Billion
Sarepta Therapeutics, Inc. SRPT $11.4 Billion
Seagen Inc. SGEN $43.2 Billion
Intercept Pharmaceuticals, Inc. ICPT $794.7 Million
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Madrigal Pharmaceuticals, Inc. MDGL $6.0 Billion
PTC Therapeutics, Inc. PTCT $3.3 Billion
Krystal Biotech, Inc. KRYS $4.2 Billion
BioXcel Therapeutics, Inc. BTAI $17.2 Million
Kodiak Sciences Inc. KOD $475.2 Million
PDS Biotechnology Corporation PDSB $54.2 Million
X4 Pharmaceuticals, Inc. XFOR $78.6 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
EXEL Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 478.1 Million $118.0 Million
Q2 2024 $ 637.2 Million $226.1 Million
Q1 2024 $ 425.2 Million $37.3 Million
Q4 2023 $ 479.7 Million $85.5 Million
Q3 2023 $ 471.9 Million $1.0 Million
Q2 2023 $ 469.8 Million $81.2 Million
Q1 2023 $ 408.8 Million $40.0 Million
Q4 2022 $ 423.9 Million -$30.2 Million

View All

EXEL Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $258.3 Million $3.0 Billion $194.4 Million $2.3 Billion
Q2 2024 $198.5 Million $2.8 Billion $198.0 Million $2.1 Billion
Q1 2024 $259.6 Million $2.8 Billion $201.5 Million $2.1 Billion
Q4 2023 $263.0 Million $2.9 Billion $189.9 Million $2.3 Billion
Q3 2023 $396.9 Million $3.0 Billion $0 $2.3 Billion
Q2 2023 $464.5 Million $3.1 Billion $194.7 Million $2.5 Billion
Q1 2023 $540.6 Million $3.1 Billion $186.9 Million $2.6 Billion
Q4 2022 $501.2 Million $3.1 Billion $190.2 Million $2.5 Billion

View All

EXEL Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $296.1 Million $24.8 Million $100.8 Million
Q2 2024 $0 $0 $0
Q1 2024 $50.6 Million -$18.2 Million -$3.4 Million
Q4 2023 -$2.6 Million -$13.1 Million -$133.9 Million
Q3 2023 $108.0 Million -$9.4 Million -$67.6 Million
Q2 2023 $25.2 Million $0 $45.7 Million
Q1 2023 $35.9 Million -$48.5 Million $39.4 Million
Q4 2022 -$38.8 Million -$112.5 Million -$174.1 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions